Centogene and alnylam pharmaceuticals launch a new clinical program aimed at revolutionizing the diagnosis of hereditary transthyretin-related amyloidosis (“attrv”)

Cambridge, mass. and rostock, germany, and berlin and munich, germany, dec. 08, 2020 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, and alnylam pharmaceuticals, inc. (“alnylam”), the leading rnai therapeutics company, announced today the launch of a new joint clinical screening program: the genetic screening of the at-risk population for hereditary t ransthy r etin-related am yloidosis and longitudinal moni toring of ttr positive subjects (the “trammoni ttr s tudy”).
CNTG Ratings Summary
CNTG Quant Ranking